These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2149184)

  • 1. Effects of platelet activating factor antagonists on arachidonic acid-induced platelet aggregation and TXA2 formation.
    Heinroth-Hoffmann I; Hauser A; Mest HJ
    Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):181-2. PubMed ID: 2149184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
    Ammit AJ; O'Neill C
    Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
    Stewart AG; Dusting GJ
    Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
    Darius H; Lefer AM
    Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
    Macconi D; Benigni A; Morigi M; Ubiali A; Orisio S; Livio M; Perico N; Bertani T; Remuzzi G; Patrono C
    J Lab Clin Med; 1989 May; 113(5):549-60. PubMed ID: 2541212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
    Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
    Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
    Ostermann G; Hofmann B; Kertscher HP; Till U
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
    Lohde C; Bahr T; Labes D; Grupe R
    Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation.
    Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH
    J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
    Sanderson HM; Heptinstall S; Vickers J; Lösche W
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
    Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
    Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.